Sanarus introduces breast biopsy
Pleasanton, CA-based Sanarus Medical may soon bring to market an ultrasound-guided biopsy tool called Centrica. The product, described as a rotational core biopsy system, uses a new approach to breast tissue sampling that the company considers more
Pleasanton, CA-based Sanarus Medical may soon bring to market an ultrasound-guided biopsy tool called Centrica. The product, described as a rotational core biopsy system, uses a new approach to breast tissue sampling that the company considers more cost-effective and less invasive than open, surgical biopsy options. The procedure creates a 3 to 4-mm incision in the breast and requires no general anesthesia or stitches. Under ultrasound visualization, a small needle is placed directly into the tissue. Once placement is confirmed via ultrasound, the immobilized lesion is “stick frozen” for a few seconds, which secures the targeted tissue and enables a large tissue sample to be removed for evaluation. Centrica, which has been cleared by the FDA, is the first in a series of ultrasound-guided technologies being developed by Sanarus.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
